Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
THOMAS HASSELL · INTERNATIONAL AIDS VACCINE INITIATIVE · 2022 · $19,938 — NIAID Process Development and Analytical Support for Development of HIV Vaccines: The development of vaccines to prevent the spread of HIV infection is among the National Institute of Allergy and Infectious Diseases (NIAID) highest priorities. While advances in immunology and molecular biology conti…
Debra Auguste · NORTHEASTERN UNIVERSITY · 2022 · $200,000 — PROJECT SUMMARY The research objective is to engineer a nanoparticle platform to bind cell receptors and inhibit cell signaling more effectively than an antibody. To date, antibodies are universally employed as antagonists due to their high binding affinity for their target cell receptor. However, t…
Joe L Hsu · STANFORD UNIVERSITY · 2022 · $634,716 — PROJECT SUMMARY/ ABSTRACT This application focuses on the contribution of transplant hemorrhage-induced iron overload in the dysregulation of pulmonary macrophages (mɸs) and the promotion of invasive aspergillosis. Aspergillus fumigatus (Af) is a ubiquitous mold that releases airborne spores (conidi…
Hana Totary-Jain · UNIVERSITY OF SOUTH FLORIDA · 2022 · $486,044 — Atherosclerotic cardiovascular disease (CVD) represents a serious affliction affecting millions globally. Despite recent advances in pharmacological and percutaneous interventions, CVD remains the leading cause of death and disability in the world. One of the main therapeutic challenges facing ather…
JINGFANG JU · NORTHPORT VA MEDICAL CENTER · 2022 — Project Summary/Abstract The goal of this application is to investigate the roles of miR-15a in colorectal cancer and to develop novel miR-15a mimic as potential therapeutics to treat advanced metastatic colorectal cancer in both male and female Veterans. Despite advancements in early detection and …
Hong Chen · BOSTON CHILDREN'S HOSPITAL · 2022 · $785,718 — PROJECT SUMMARY/ABSTRACT Atherosclerosis is the leading cause of life-threatening coronary heart disease, ischemic stroke, and peripheral arterial disease in the United States. Notably, dyslipidemia remains a major risk factor despite effective lipid- lowering therapies and prevention programs. This…
Rajagopal Ramesh · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · 2022 · $343,921 — Effective control of lung cancer continues to remain a clinical challenge resulting in poor five-year survival rate. Currently available therapies while showing promise have had limitations. Therefore, continued efforts for developing new therapeutic agents and systemic treatment modalities are warr…
Qiaobing Xu · TUFTS UNIVERSITY MEDFORD · 2022 · $348,007 — PROJECT SUMMARY Intracellular protein therapies are tremendously appealing, promising treatments for many heretofore untreatable diseases, including genetic diseases and cancers. However, the safe, efficient intracellular delivery of proteins remains a challenge. Here we propose the development of a…
Raul Andino · ALEPH THERAPEUTICS, INC. · 2022 · $295,928 — SUMMARY The Covid-19 pandemic caused by Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) is currently the most important public health crisis in the world. Given the unprecedented scope of this disease, it is critical to explore novel strategies to mitigate this crisis. Aleph Therapeutics and UC…
Youzhong Guo · VIRGINIA COMMONWEALTH UNIVERSITY · 2022 · $382,600 — SUMMARY Membrane proteins play crucial roles in living organisms. Protein-lipid interactions are crucial for the structural and functional integrity of membrane proteins. High-resolution of membrane protein structures are in high-demand for both understanding their biology and structure-based drug d…
Zhaoyang Liu · UNIVERSITY OF SOUTHERN CALIFORNIA · 2022 · $92,610 — Project Summary Osteoarthritis (OA) is the most common form of degenerative joint disease affecting millions of people worldwide and lead to a tremendous financial burden. Currently there are no disease modifying therapies available for OA, due to limited understanding of the genetic factors and pat…
Youzhong Guo · VIRGINIA COMMONWEALTH UNIVERSITY · 2022 · $236,127 — Project Summary for Parent Grant R01GM132329 Membrane proteins are essential in living organisms. Protein-lipid interactions are critical for membrane protein structural and functional integrity. High-resolution membrane protein structures are in high demand for understanding their biology and drug …
THOMAS Elliott VAN DYKE · ADA FORSYTH INSTITUTE, INC. · 2022 · $458,494 — Project Summary Uncontrolled inflammation is a major impediment to tissue engineering, regeneration and reconstruction of both diseased and injured tissues resulting in further tissue injury, tissue scarring and fibrosis. Stem cell activity is disrupted by persistent signals promoting inflammation, …
Kent Lai · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · 2022 · $190,625 — PROJECT SUMMARY / ABSTRACT Hereditary deficiency of galactose-1-phosphate uridylyltransferase (GALT, E.C. 2.7.7.12) activity in humans can lead to a potentially lethal disease called Classic Galactosemia (OMIM 230400). Despite the life-saving consequences of newborn screening, early diagnosis, and …
ROBERT M LAVKER · NORTHWESTERN UNIVERSITY AT CHICAGO · 2022 · $2,791,371 — Northwestern University (NU) is recognized for its strong interdisciplinary cutaneous, ocular, nanotechnology and immunology research programs with particular strength in investigations related to wound repair and inflammation. Leveraging these strengths, the theme of the NU CounterAct Center of Exc…
Shuxia Wang · UNIVERSITY OF KENTUCKY · 2022 · $491,417 — Obesity is an independent risk factor for development of non-alcoholic fatty liver disease (NAFLD). With the epidemic burden of obesity and metabolic diseases, NAFLD occurrence is steadily rising, along with the need for therapeutic options of this disease. Preliminary data from rodent and human stu…
Mark Andrew Borden · UNIVERSITY OF COLORADO · 2022 · $345,230 — The development of new pharmaceuticals for the treatment of brain cancer and neurological disease has outpaced our ability to deliver them safely, largely due to the blood-brain barrier (BBB). Bypassing the BBB to access the brain parenchyma is often highly invasive, involving surgery to remove part…
WADIH ARAP · RBHS -CANCER INSTITUTE OF NEW JERSEY · 2022 · $629,467 — ABSTRACT Eight percent of patients diagnosed with prostate cancer progress to lethal metastatic disease. Development of resistance to androgen-deprivation therapy and eventually, to last line chemotherapeutics such as enzalutamide (ENZ), contribute to lethal, metastatic prostate cancer. While intere…
John Ramunas · REJUVENATION TECHNOLOGIES, INC. · 2022 · $299,987 — Abstract Short telomeres, the DNA tips of chromosomes, drive multiple key pathogenic mechanisms identified in idiopathic pulmonary fibrosis (IPF) patients. Rejuvenation Technologies is developing the first safe and effective intervention to extend short telomeres in lung and thereby extend IPF patie…
Zhaoyang Liu · UNIVERSITY OF TEXAS AT AUSTIN · 2022 · $1 — Project Summary Osteoarthritis (OA) is the most common form of degenerative joint disease affecting millions of people worldwide and lead to a tremendous financial burden. Currently there are no disease modifying therapies available for OA, due to limited understanding of the genetic factors and pat…